Scholarlink

<p>Pre-transplantation red blood cell transfusion (RBCT) is a well-recognized cause of allosensitization. However, the effects of RBCT after kidney transplantation remain controversial. This study evaluates the impacts of RBCT within the first 30 days post-transplantation (early RBCT) with regard to long-term patient and graft outcomes. We retrospectively analyzed 785 patients who underwent HLA- and ABO-compatible kidney transplantation between 2014 and 2020. Patients were categorized based on whether they received early RBCT. Overall, 18.9% of patients received early RBCT. On multivariable analysis, early RBCT was independently associated with increased risks of all-cause mortality (hazard ratio, 2.264; 95% CI 1.186–4.324; <i>P</i> = 0.013) and death-censored graft loss (hazard ratio, 1.995; 95% CI 1.045–3.810; <i>P</i> = 0.036). Cumulative incidence of antibody-mediated rejection was significantly higher in the early RBCT group (<i>P</i> = 0.024). In the sensitivity analysis, the early RBCT significantly increased the risk of patient mortality (<i>P</i> = 0.017), death-censored graft loss (<i>P</i> = 0.018) and antibody-mediated rejection (<i>P</i> = 0.05), regardless of the donor profile. Early post-transplantation RBCT was associated with increased risks of all-cause mortality, graft loss, and antibody-mediated rejection, highlighting the need for reconsideration of transfusion practices following kidney transplantation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical implications of early blood transfusion after kidney transplantation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月25日

查看全文
  • Minyu Kang,
  • Hwa-Hee Koh,
  • Seung Hyuk Yim,
  • Mun Chae Choi,
  • Hyun Jeong Kim,
  • Hyung Woo Kim,
  • Jaeseok Yang,
  • Beom Seok Kim,
  • Kyu Ha Huh,
  • Myoug Soo Kim,
  • Juhan Lee

摘要

Pre-transplantation red blood cell transfusion (RBCT) is a well-recognized cause of allosensitization. However, the effects of RBCT after kidney transplantation remain controversial. This study evaluates the impacts of RBCT within the first 30 days post-transplantation (early RBCT) with regard to long-term patient and graft outcomes. We retrospectively analyzed 785 patients who underwent HLA- and ABO-compatible kidney transplantation between 2014 and 2020. Patients were categorized based on whether they received early RBCT. Overall, 18.9% of patients received early RBCT. On multivariable analysis, early RBCT was independently associated with increased risks of all-cause mortality (hazard ratio, 2.264; 95% CI 1.186–4.324; P = 0.013) and death-censored graft loss (hazard ratio, 1.995; 95% CI 1.045–3.810; P = 0.036). Cumulative incidence of antibody-mediated rejection was significantly higher in the early RBCT group (P = 0.024). In the sensitivity analysis, the early RBCT significantly increased the risk of patient mortality (P = 0.017), death-censored graft loss (P = 0.018) and antibody-mediated rejection (P = 0.05), regardless of the donor profile. Early post-transplantation RBCT was associated with increased risks of all-cause mortality, graft loss, and antibody-mediated rejection, highlighting the need for reconsideration of transfusion practices following kidney transplantation.